Article
Pharmacology & Pharmacy
Xavier Cortes, Joaquin Borras-Blasco, Laura Flor, Beatriz Antequera, Sergio Fernandez-Martinez, Jose Ramon Moles, Elvira Castera
Summary: In this case report, a 60-year-old man with ulcerative colitis refractory to azathioprine, infliximab, and adalimumab achieved successful remission with golimumab therapy. The patient showed significant improvement and sustained remission after switching to golimumab treatment, suggesting that golimumab may be an effective option for patients who do not respond to infliximab and adalimumab. Further studies are needed to confirm the efficacy of golimumab as a rescue treatment for refractory ulcerative colitis.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
(2021)
Article
Pharmacology & Pharmacy
Jill L. Kinzer, Troy A. Halseth, Jukyung Kang, Sang Yeop Kim, Preethi Kumaran, Michael Ford, Sergei Saveliev, St John Skilton, Anna Schwendeman
Summary: FDA-approved anti-TNF alpha biopharmaceuticals have been successful in treating autoimmune diseases, but there are product-specific differences in patient outcomes, possibly due to structural and functional differences. In this study, we compared the structural and functional differences among three anti-TNF alpha mAbs (Humira (R), Remicade (R), and Simponi Aria (R)) to understand their implications on efficacy.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Medicine, General & Internal
Naohiko Kinoshita, Kazuki Kakimoto, Hikaru Shimizu, Koji Nishida, Keijiro Numa, Yuka Kawasaki, Hideki Tawa, Kei Nakazawa, Ryoji Koshiba, Yuki Hirata, Naokuni Sakiyama, Eiko Koubayashi, Toshihisa Takeuchi, Takako Miyazaki, Kazuhide Higuchi, Shiro Nakamura, Hiroki Nishikawa
Summary: This study evaluated the role of serum biomarkers in predicting the efficacy of golimumab in bio-naive patients with UC. The results suggest that IL-13 may be a potential biomarker to predict the response to golimumab treatment.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Alix Demaris, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper Steenholdt, Jakob B. Seidelin, Wilhelm Huisinga, Robin Michelet, Linda B. S. Aulin, Charlotte Kloft
Summary: This review aims to analyze the population PK models of infliximab (IFX) in patients with ulcerative colitis (UC) and acute severe UC (ASUC), and assess the impact of disease activity on IFX PK. The results showed that there are still many gaps in the current research, such as a limited number of models specifically developed for UC patients, a lack of studies on severe UC patients, and a lack of evaluation of predictive performance for the models. Therefore, more comprehensive research and adequate reporting and evaluation of the models are needed for clinical application.
Review
Gastroenterology & Hepatology
Edo H. J. Savelkoul, Pepijn W. A. Thomas, Lauranne A. A. P. Derikx, Nathan den Broeder, Tessa E. H. Romkens, Frank Hoentjen
Summary: Loss of response to infliximab or adalimumab in ulcerative colitis occurs frequently, with an annual rate of 10% for infliximab and 13% for adalimumab. Dose escalation rates were higher than loss of response, with 72% and 52% regaining clinical benefit for infliximab and adalimumab, respectively. Uniform definitions are needed for more robust evaluations.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Medicine, General & Internal
Benjamin L. Gordon, Robert Battat
Summary: Therapeutic drug monitoring (TDM) is a useful strategy in ulcerative colitis (UC), particularly in acute severe UC (ASUC). While there is limited data available for the use of TDM of infliximab in ASUC, observational data suggest that higher serum infliximab concentrations and lower clearance are associated with better clinical outcomes and decreased rates of colectomy. However, more studies are needed to evaluate optimal dosing and TDM targets in this population.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Robert Gilmore, Wei Lian Tan, Richard Fernandes, Yoon-Kyo An, Jakob Begun
Summary: This study found that upadacitinib may be a safe and effective salvage therapy for patients with steroid-refractory acute severe ulcerative colitis who have previously failed to respond to infliximab therapy. Prospective studies are needed to determine the safety and efficacy of upadacitinib use in this setting before routine use can be recommended.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
David T. Rubin, Iris Dotan, Aaron DuVall, Yoram Bouhnik, Graham Radford-Smith, Peter D. R. Higgins, Daniel S. Mishkin, Pablo Arrisi, Astrid Scalori, Young S. Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, Julian Panes
Summary: Etrolizumab showed superiority over placebo in inducing remission in HIBISCUS I, but not in HIBISCUS II. Etrolizumab was well tolerated in both studies.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, John K. Marshall, Jean-Frederic Colombel, Parambir S. Dulai, Walter Reinisch
Summary: For patients with moderate to severe biologic naive UC, infliximab and vedolizumab have similar efficacy in improving clinical symptoms, but infliximab has higher rates of corticosteroid-free clinical remission (CR) and endoscopic remission (ER) after 1 year of treatment.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Rachel Levy, Manar Matar, Maya Zvuloni, Raanan Shamir, Amit Assa
Summary: TC response to adjustment of anti-TNFa treatment can be predicted for adalimumab but not for infliximab. Decreasing interval for adalimumab results in increased TC, while increasing interval for adalimumab and dose increase for infliximab both lead to decreased TC.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2023)
Article
Gastroenterology & Hepatology
Stefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkus, Maciej Kowalski, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Mi Rim Kim, Seul Gi Lee, Byong Duk Ye, Walter Reinisch
Summary: This study demonstrated the pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, with comparable clinical remission rates between the two formulations.
Article
Pediatrics
Jennifer C. C. deBruyn, Kevan Jacobson, Wael El-Matary, Eytan Wine, Matthew W. Carroll, Caitlin Goedhart, Remo Panaccione, Iwona T. Wrobel, Hien Q. Huynh
Summary: The study evaluated the relationship between serum infliximab concentrations during induction and short-term clinical remission in children with ulcerative colitis. Higher infliximab concentrations prior to the second dose were associated with week 8 clinical remission. Young age and low body weight impact infliximab concentration, prompting the need for proactive adjustment in pediatric patients with ulcerative colitis.
FRONTIERS IN PEDIATRICS
(2021)
Article
Gastroenterology & Hepatology
Ami Kawamoto, Toshimitsu Fujii, Ryuji Mitani, Yasuhiro Suzuki, Tsunehito Yauchi, Ryuichi Okamoto
Summary: This article reports for the first time the serum drug levels and long-term health status of the child of a patient treated with CT-P13 throughout her pregnancy.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Gaurav Syal, Lori Robbins, Amir Kashani, Nirupama Bonthala, Edward Feldman, Phillip Fleshner, Eric Vasiliauskas, Dermot McGovern, Christina Ha, Stephan Targan, Gil Y. Melmed
Summary: Serum albumin and band neutrophil percentage are independent predictors of failure of infliximab rescue therapy in patients with acute severe ulcerative colitis. The combination of serum albumin <= 2.5 g/dl and band neutrophil count >= 13% has a 100% positive predictive value for 90-day colectomy.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Daniela Pugliese, Giuseppe Privitera, Francesca Rogai, Angela Variola, Anna Viola, Lucrezia Laterza, Antonino C. Privitera, Mariangela Allocca, Fabrizio Bossa, Maria Cappello, Marco Daperno, Greta Lorenzon, Silvia Mazzuoli, Mariabeatrice Principi, Renato Sablich, Luisa Moser, Antonio Ferronato, Sara Traini, Gherardo Tapete, Giorgia Bodini, Maria Di Girolamo, Laurino Grossi, Giammarco Mocci, Chiara Ricci, Simone Saibeni, Stefano Festa, Rocco Spagnuolo, Claudio C. Cortelezzi, Filippo Mocciaro, Fernando Rizzello, Alessandro Armuzzi
Summary: This study investigated the long-term outcomes of patients with ulcerative colitis on golimumab therapy. Results showed that being biological-naive and able to discontinue steroids at Weeks 8 and 14 were associated with longer persistence on golimumab therapy. Maintaining continuous clinical response also led to a lower likelihood of golimumab discontinuation.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2021)
Review
Gastroenterology & Hepatology
Brigida Barberio, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: This study conducted a network meta-analysis to compare the relative efficacy of various biological therapies and small molecules in the treatment of luminal Crohn's disease. The results showed differences in the effectiveness of different drugs in inducing and maintaining clinical remission, and previous exposure to biologics also had an impact on treatment outcomes.
Letter
Gastroenterology & Hepatology
Conchubhair Winters, Alexander Charles Ford
Review
Gastroenterology & Hepatology
Brigida Barberio, Pierfrancesco Visaggi, Edoardo Savarino, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford
Summary: This study conducted a network meta-analysis to evaluate the efficacy and safety of different medical therapies for endoscopy-negative reflux disease. The results showed that proton pump inhibitors (PPIs) are superior to other drugs in treating this condition. Future research should focus on better patient classification and investigating the efficacy of other drugs.
NEUROGASTROENTEROLOGY AND MOTILITY
(2023)
Review
Gastroenterology & Hepatology
Shahida Din, Christian P. Selinger, Christopher J. Black, Alexander C. Ford
Summary: A network meta-analysis was conducted to examine the risk of Herpes zoster infection associated with biologics and small molecules used to treat inflammatory bowel disease (IBD). The results showed that Janus kinase inhibitors, particularly tofacitinib, were most likely to increase the risk of Herpes zoster infection, and the risk increased with higher doses.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Vivek C. Goodoory, Cho E. Ng, Christopher J. Black, Alexander C. Ford
Summary: This article is associated with Goodoory et al papers. Click the link to access these articles.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Alexander C. Ford, Colin W. Howden
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Mais Khasawneh, Orla F. Craig, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: The study suggests that diagnosing IBS according to the Rome IV criteria and conducting limited investigation is safe and durable. Among IBS patients, although 1 in 6 were referred again due to gastrointestinal symptoms, missed organic gastrointestinal disease occurred in only 1% of patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Letter
Gastroenterology & Hepatology
Maria rosa Ingrosso, Christopher j. Black, Alexander c. Ford
Article
Gastroenterology & Hepatology
Christy Riggott, Keeley M. Fairbrass, Christopher J. Black, David J. Gracie, Alexander C. Ford
Summary: Using latent class analysis, this study identified novel clusters of patients with inflammatory bowel disease (IBD) and found that patients with higher gastrointestinal and psychological symptoms were at a higher risk of adverse disease outcomes and were also high-volume users of healthcare.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Gastroenterology & Hepatology
Kee-Huat Chuah, Christopher J. Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong-Yeh Lee, Sanjiv Mahadeva, Alexander C. Ford
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Gastroenterology & Hepatology
Vivek C. Goodoory, Mais Khasawneh, Christopher J. Black, Eamonn M. M. Quigley, Paul Moayyedi, Alexander C. Ford
Summary: This article conducted a meta-analysis to study the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). The study found that certain combinations of probiotics or strains may be beneficial for IBS, but the certainty of the evidence was low.
Review
Gastroenterology & Hepatology
Pierfrancesco Visaggi, Brigida Barberio, Giulio Del Corso, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford, Edoardo Savarino
Summary: A network meta-analysis was conducted to compare the efficacy of different drugs for active eosinophilic esophagitis (EoE). The results showed that most available drugs were more effective than placebo in treating EoE. However, significant heterogeneity among the trials hindered the establishment of a solid therapeutic hierarchy.
Article
Gastroenterology & Hepatology
Christy Riggott, Keeley M. Fairbrass, Christian P. Selinger, David J. Gracie, Alexander C. Ford
Summary: The use of opioids in patients with inflammatory bowel disease (IBD) is associated with psychological comorbidity and an increased risk of intestinal resection, particularly with stronger formulations. Future studies should classify the risks of different opioids to develop reliable prescribing algorithms, and evaluate the effectiveness of addressing psychological factors as an opioid avoidance strategy in routine IBD care.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Brigida Barberio, Keeley M. Fairbrass, David J. Gracie, Alexander C. Ford
Summary: In this 12-month longitudinal study, one-third of patients with IBD reported presence of Rome III IBS-type symptoms at any point in time. Reporting such symptoms was associated with significant impacts on psychological health and/or quality of life.
NEUROGASTROENTEROLOGY AND MOTILITY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Mais Khasawneh, Orla F. Craig, David J. Gracie, Christopher J. Black, Alexander C. Ford